Loading…
Reported covered position: Office of Senator Tester, Congressional Science Fellow (Sep 2011 - Aug 2012); Office of Senator Brown, Health Legislative Assistant (Aug 2012 - Jan 2015)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NEUROCRINE BIOSCIENCES, INC · Firm:
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2026 · third_quarter · Q3
Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services and the Department of Veterans Affairs for physical conditions associated with mental illness, such as Tardive Dyskinesia.
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
Source: Senate LDA
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
Telemental Health Care Access Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Telemental Health Care Access Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Telemental Health Care Access Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Tax Relief for American Families and Workers Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.
Tax Relief for American Families and Workers Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.
Tax Relief for American Families and Workers Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.
Telehealth Modernization Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Telehealth Modernization Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Telehealth Modernization Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act
Telemental Health Care Access Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Telemental Health Care Access Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Telemental Health Care Access Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Telemental Health Care Access Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Tax Relief for American Families and Workers Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.
Tax Relief for American Families and Workers Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.
Tax Relief for American Families and Workers Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.
Tax Relief for American Families and Workers Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.
Telehealth Modernization Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Telehealth Modernization Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Telehealth Modernization Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Telehealth Modernization Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Telemental Health Care Access Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the diagnosis and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432. H.R. 7085 - BIOSECURE Act.
Telemental Health Care Access Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the diagnosis and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. H.R. 7085 - BIOSECURE Act.
Telemental Health Care Access Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the diagnosis and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432. H.R. 7085 - BIOSECURE Act.
Telemental Health Care Access Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the diagnosis and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. H.R. 7085 - BIOSECURE Act.
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 5539 - Orphan Cures Act H.R. 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act.
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 5539 - Orphan Cures Act H.R. 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act.
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 5539 - Orphan Cures Act H.R. 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act.
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 5539 - Orphan Cures Act H.R. 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act.
Tax Relief for American Families and Workers Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024.
Tax Relief for American Families and Workers Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024.
Tax Relief for American Families and Workers Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024.
Tax Relief for American Families and Workers Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024.
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the diagnosis and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432. H.R. 7085 - BIOSECURE Act.
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the diagnosis and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. H.R. 7085 - BIOSECURE Act.
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the diagnosis and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432. H.R. 7085 - BIOSECURE Act.
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the diagnosis and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. H.R. 7085 - BIOSECURE Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 5539 - Orphan Cures Act H.R. 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 5539 - Orphan Cures Act H.R. 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 5539 - Orphan Cures Act H.R. 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 5539 - Orphan Cures Act H.R. 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act.
Telehealth Modernization Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the diagnosis and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. H.R. 7085 - BIOSECURE Act.
Telehealth Modernization Act of 2024
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the diagnosis and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. H.R. 7085 - BIOSECURE Act.
To amend the FAA Modernization and Reform Act of 2012 and title 49, United States Code, with respect to disadvantaged business enterprises, and for other purposes.
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
To amend the FAA Modernization and Reform Act of 2012 and title 49, United States Code, with respect to disadvantaged business enterprises, and for other purposes.
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
To amend the FAA Modernization and Reform Act of 2012 and title 49, United States Code, with respect to disadvantaged business enterprises, and for other purposes.
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Telemental Health Care Access Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Telemental Health Care Access Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Telemental Health Care Access Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Revoke Iranian Funding Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Revoke Iranian Funding Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Revoke Iranian Funding Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Revoke Iranian Funding Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Restore VA Accountability Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Restore VA Accountability Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Restore VA Accountability Act of 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Consolidated Appropriations Act, 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Consolidated Appropriations Act, 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Consolidated Appropriations Act, 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Consolidated Appropriations Act, 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Inflation Reduction Act of 2022
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Potential changes to structure and reimbursement for Medicare Part D; H.R.5376 - Inflation Reduction Act of 2022 - issues related to implementation.
Inflation Reduction Act of 2022
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
H.R.5376 - Inflation Reduction Act of 2022 - Issues related to the Orphan Drug Tax Credit.
Inflation Reduction Act of 2022
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
H.R.5376 - Inflation Reduction Act of 2022 - Issues related to the Orphan Drug Tax Credit.
Inflation Reduction Act of 2022
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
H.R.5376 - Inflation Reduction Act of 2022 - Issues related to the Orphan Drug Tax Credit.
Inflation Reduction Act of 2022
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
H.R.5376 - Inflation Reduction Act of 2022 - Issues related to the Orphan Drug Tax Credit.
Inflation Reduction Act of 2022
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Potential changes to structure and reimbursement for Medicare Part D; H.R.5376 - Inflation Reduction Act of 2022 - issues related to implementation.
Inflation Reduction Act of 2022
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Potential changes to structure and reimbursement for Medicare Part D; H.R.5376 - Inflation Reduction Act of 2022 - issues related to implementation.
Inflation Reduction Act of 2022
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Potential changes to structure and reimbursement for Medicare Part D; H.R.5376 - Inflation Reduction Act of 2022 - issues related to implementation.
Telemental Health Care Access Act of 2021
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Consolidated Appropriations Act, 2023
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Elijah E. Cummings Lower Drug Costs Now Act
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Potential changes to structure and reimbursement for Medicare Part D; HR 3 Elijah E. Cummings Lower Drug Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 - Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Potential changes to structure and reimbursement for Medicare Part D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Potential changes to structure and reimbursement for Medicare Part D; HR 3 Elijah E. Cummings Lower Drug Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 - Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Potential changes to structure and reimbursement for Medicare Part D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
Reduced Costs and Continued Cures Act
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Potential changes to structure and reimbursement for Medicare Part D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
Reduced Costs and Continued Cures Act
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Potential changes to structure and reimbursement for Medicare Part D; HR 3 Elijah E. Cummings Lower Drug Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 - Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
Reduced Costs and Continued Cures Act
Client: NEUROCRINE BIOSCIENCES, INC · Firm: NEUROCRINE BIOSCIENCES, INC
Potential changes to structure and reimbursement for Medicare Part D; HR 3 Elijah E. Cummings Lower Drug Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 - Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2026 · second_quarter · Q2
Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services and the Department of Veterans Affairs for physical conditions associated with mental illness, such as Tardive Dyskinesia.
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2026 · first_quarter · Q1
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services and the Department of Veterans Affairs for physical conditions associated with mental illness, such as Tardive Dyskinesia.
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2025 · fourth_quarter · Q4
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for physical conditions associated with mental illness, such as Tardive Dyskinesia.
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2025 · third_quarter · Q3
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for physical conditions associated with mental illness, such as Tardive Dyskinesia.
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2025 · second_quarter · Q2
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2025 · first_quarter · Q1
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. Issues related to the Rare Pediatric Priority Review Voucher Program.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2024 · fourth_quarter · Q4
Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the diagnosis and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. H.R. 7085 - BIOSECURE Act.
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2024 · third_quarter · Q3
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 5539 - Orphan Cures Act H.R. 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act.
Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2024 · second_quarter · Q2
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the diagnosis and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432. H.R. 7085 - BIOSECURE Act.
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024.
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 5539 - Orphan Cures Act H.R. 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2024 · first_quarter · Q1
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 5539 - Orphan Cures Act H.R. 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act.
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024.
Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2023 · fourth_quarter · Q4
Support appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
H.R.5376 - Inflation Reduction Act of 2022 - Issues related to the Orphan Drug Tax Credit.
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2023 · third_quarter · Q3
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Support appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2023 · second_quarter · Q2
Potential changes to structure and reimbursement for Medicare Part D; H.R.5376 - Inflation Reduction Act of 2022 - issues related to implementation.
Support appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R.3432 - Telemental Health Care Access Act of 2023. H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2023 · first_quarter · Q1
Potential changes to structure and reimbursement for Medicare Part D; H.R.5376 - Inflation Reduction Act of 2022 - issues related to implementation.
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2022 · fourth_quarter · Q4
Support appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
H.R.5376 - Inflation Reduction Act of 2022 - Issues related to the Orphan Drug Tax Credit.
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2022 · third_quarter · Q3
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
H.R. 5376 Build Back Better Act - Issues related to the Orphan Drug Tax Credit.
Potential changes to structure and reimbursement for Medicare Part D; HR 3 Elijah E. Cummings Lower Drug Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 - Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2022 · second_quarter · Q2
Potential changes to structure and reimbursement for Medicare Part D; HR 3 Elijah E. Cummings Lower Drug Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 - Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
Support appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Regulatory and legislative health care issues impacting pricing and access; Issues related to diagnosis and treatment of Tardive Dyskinesia; Issues related to diagnosis and treatment of Parkinsons Disease. Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2022 · first_quarter · 1A
H.R. 5376 Build Back Better Act - Issues related to the Orphan Drug Tax Credit.
Potential changes to structure and reimbursement for Medicare Part D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2022 · first_quarter · Q1
Potential changes to structure and reimbursement for Medicare Part D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2021 · fourth_quarter · 4A
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 4439/S.4010, Creating Hope Reauthorization Act; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2021 · fourth_quarter · Q4
Potential changes to structure and reimbursement for Medicare Part D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
H.R. 5376 Build Back Better Act - Issues related to the Orphan Drug Tax Credit.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2021 · third_quarter · Q3
Potential changes to structure and reimbursement for Medicare Part D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 Reduced Costs and Continued Cures Act.
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 4439/S.4010, Creating Hope Reauthorization Act; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act.
NEUROCRINE BIOSCIENCES, INC via NEUROCRINE BIOSCIENCES, INC
2021 · second_quarter · Q2
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Telehealth; H.R. 4439/S. 4010, Creating Hope Reauthorization Act; H.R. 2507 / S. 2158, Newborn Screening Saves Lives Reauthorization Act; and S. 2061, Telemental Healthcare Access Act of 2021.
Potential changes to structure and reimbursement for Medicare Part D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for physical conditions associated with mental illness, such as Tardive Dyskinesia.
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for physical conditions associated with mental illness, such as Tardive Dyskinesia.
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024. Issues related to the Orphan Drug Tax Credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 5539 - Orphan Cures Act H.R. 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the diagnosis and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432, and the Telehealth Modernization Act of 2024, H.R. 7623. H.R. 7085 - BIOSECURE Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the diagnosis and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432. H.R. 7085 - BIOSECURE Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Potential changes to structure and reimbursement for Medicare Part D; H.R.5376 - Inflation Reduction Act of 2022 - issues related to implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R.5376 - Inflation Reduction Act of 2022 - Issues related to the Orphan Drug Tax Credit.
Potential changes to structure and reimbursement for Medicare Part D; H.R.5376 - Inflation Reduction Act of 2022 - issues related to implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R.5376 - Inflation Reduction Act of 2022 - Issues related to the Orphan Drug Tax Credit.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R.5376 - Inflation Reduction Act of 2022 - Issues related to the Orphan Drug Tax Credit.
Support appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Potential changes to structure and reimbursement for Medicare Part D; H.R.5376 - Inflation Reduction Act of 2022 - issues related to implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Support appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 5376 Build Back Better Act - Issues related to the Orphan Drug Tax Credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 5376 Build Back Better Act - Issues related to the Orphan Drug Tax Credit.
Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Potential changes to structure and reimbursement for Medicare Part D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
H.R. 5376 Build Back Better Act - Issues related to the Orphan Drug Tax Credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 4439/S.4010, Creating Hope Reauthorization Act; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE